Knowledge Resource Center for Ecological Environment in Arid Area
| Development of a pregnant rat model for treating methamphetamine abuse with monoclonal antibodies | |
| White, Sarah J. | |
| 出版年 | 2008 |
| 学位类型 | 博士 |
| 导师 | Owens, S. Michael |
| 学位授予单位 | University of Arkansas for Medical Sciences |
| 英文摘要 | The first set of studies hypothesized that chronic maternal administration of (+)-methamphetamine (METH; 5.6-17.8 mg/kg/day) from gestational day 7 (GD7; before organogenesis) to GD21 (1-2 days antepartum) results in dose- and gestational time-dependent effects in pregnant rats and litters. METH dose- and gestational time-dependent health and behavioral effects were found in the pregnant rats, whereby rats either recovered from METH-induced effects by mid-gestation or died. Litters of the surviving dams were similar in litter size and weight to controls by GD21. Late-gestational stage reductions in METH systemic clearance were found in the dams, which were dose-independent. Although the maternal and fetal serum concentrations of METH and its metabolite (+)-amphetamine (AMP) were similar, METH and AMP fetal brain concentrations were three-fold lower. The second set of studies hypothesized that acute METH dosing during early- and late-stage pregnancy causes dose- and gestational time-dependent METH and AMP pharmacokinetics. Timed-pregnant rats received either 1 mg/kg iv METH on GD7 or 1, 3 or 5.6 mg/kg iv METH on GD21. The results showed gestational time-dependent reductions in clearance between GD7 and GD21 but dose-independent pharmacokinetics on GD21. The final studies hypothesized that high-affinity anti-METH/AMP monoclonal antibody (mAb) protects pregnant rats and litters from adverse effects by redistributing METH and AMP from their brains. Pregnant rats received 1 mg/kg iv METH on GD21, followed 30 min later by administration of vehicle or anti-METH/AMP mAb. MAb-treated maternal serum METH and AMP concentrations remained substantially elevated due to a >400% rise in METH and AMP serum protein binding. Fetal serum METH and AMP protein binding also increased, but fetal serum METH and AMP concentrations were lower. Maternal and fetal brain METH and AMP concentrations were also lower after mAb treatment, but returned to control levels by 5 h. In conclusion, METH and AMP maternal pharmacokinetics were altered during late-stage pregnancy in chronically and acutely dosed rats, suggesting enhanced vulnerability before delivery. Anti-METH/AMP mAb offered acute protection by reducing maternal and fetal brain METH and AMP concentrations during peak exposure. These studies show promise for maternal and fetal protection from METH and AMP exposure by treatment with anti-METH/AMP mAb. |
| 英文关键词 | Drug abuse Fetal protection Methamphetamine Monoclonal antibodies Pregnant |
| 语种 | 英语 |
| 国家 | United States |
| 来源学科分类 | Medicine; Pharmacology; Immunology |
| URL | https://pqdtopen.proquest.com/doc/304410122.html?FMT=AI |
| 来源机构 | University of Arkansas for Medical Sciences |
| 资源类型 | 学位论文 |
| 条目标识符 | http://119.78.100.177/qdio/handle/2XILL650/244243 |
| 推荐引用方式 GB/T 7714 | White, Sarah J.. Development of a pregnant rat model for treating methamphetamine abuse with monoclonal antibodies[D]. University of Arkansas for Medical Sciences,2008. |
| 条目包含的文件 | 条目无相关文件。 | |||||
| 个性服务 |
| 推荐该条目 |
| 保存到收藏夹 |
| 导出为Endnote文件 |
| 谷歌学术 |
| 谷歌学术中相似的文章 |
| [White, Sarah J.]的文章 |
| 百度学术 |
| 百度学术中相似的文章 |
| [White, Sarah J.]的文章 |
| 必应学术 |
| 必应学术中相似的文章 |
| [White, Sarah J.]的文章 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
